

# Metrology for Metal Metabolism Disorders

EUROPEAN  
METROLOGY  
NETWORKS



TRACE LAB MED



METROLOGY IN  
CHEMISTRY

**Heidi Goenaga Infante, LGC NML, UK**  
***Email: [Heidi.Goenaga-Infante@lgcgroup.com](mailto:Heidi.Goenaga-Infante@lgcgroup.com)***

**4 | 10 November 2021**  
**Pandemics | Laboratory Medicine**

# Background


- Some of the physiologically relevant trace elements include iodine, copper, iron, manganese, zinc, selenium, cobalt and molybdenum
- They are needed in certain amounts for normal physiology but accumulation or deficiency can cause known disorders, e.g.

**Cu** and Wilson disease (increased tissue Cu) and, Menkes disease (decreased Cu/Cu-Ceruloplasmin)


**Fe** and hemochromatosis (increased body Fe)

**Zn** and achrodermatitis enteropathica (decreased Zn, impaired function of Zn enzymes)

- Diagnosis usually involves gene mutation testing, clinical observations and bio-chemical testing, e.g.
  - Wilson disease: Non Ceruloplasmin (CER)-bound Cu
  - Hemochromatosis: Total blood Fe, serum ferritin (light chain), liver Fe (MRI)



**Achrodermatitis**



**Wilson disease (Kayser-Fleischer ring)**

# Need of metrological traceability for biomarkers of metal disorders: Current challenges of bio-medical analytical methods



- Exchangeable Cu = Total Cu – CuCER. CER by nephelometry: The anti-CER antibody used is not specific to holoCER so the assay can overestimate the concentration of CER due to the presence of the apoCER.
- Off line ultra-filtration based methods based on complexation of exchangeable Cu (Cu mainly bound to albumin) and with EDTA have been found to provide biased results<sup>1</sup>
- WHO recognizes that ferritin is typically assessed in serum or plasma with enzyme immunoassays after blood collection but, there is no specific recommendation on variability among analytical methods and commutability
- WHO International Standard (NIBSC, 94/572) produced for light chain ferritin from E. Coli spiked to cryosupernatant plasma for immunoassays (6.3 µg/ampoule with a variance of the ampoule content: ± 0.345%)
- Reference methodology (IDMS based) published for ferritin from animal tissue extracts<sup>2</sup> but lack of SI traceable methodology for human plasma/serum ferritin
- Need for SI traceable methods and reference materials to underpin/validate bio-chemical tests for diagnostics

## CCQM activities

- K162 (Selenoproteins in human plasma)
- P201 (Total Haemoglobin in human whole blood)

## Previous EMPIR projects



- EMRP HLT05: Metrology for Metalloproteins
- EMPIR 15HLT02 REMIND  
Role of metals and metal containing biomolecules in neurodegenerative diseases

<sup>1</sup> Del Castillo Busto et al., *Anal. Bioanal. Chem.*, 2021; DOI: 10.1007/s00216-021-03517-y

<sup>2</sup> A Tchaikovsky et al., *Metrologia*, 2020; 042101.

# Metal Metabolism Disorders (MMD): Other Measurement Needs

- **Quantitative imaging** strategies needed to determine drug distribution down to single cells in pre-clinical samples (help understand drug efficacy and potential toxicity routes)
  - Elemental imaging methods are potential tools to address this need but,
  - Standards and quantitative strategies need development and characterisation
  - Laboratory performance inter-comparison is essential
- **Novel biomarkers of MMD**
  - Isotopic measurements proposed as complementary to other biomarker measurements to help validate diagnosis of MMD (Cu IR in serum and liver disease e.g. Wilson Disease)
  - Methods for bulk IR have been published<sup>1</sup> but further effort needed for validation of determination of isotopic signatures/variation of specific-species



<sup>1</sup>M. Armendia, et al., DOI: 10.1039/C3JA30349G.

# Proposed Research Topic shall address:

- Protocols for selection, preparation, fractionation, mounting and preconcentration of samples (e.g. tissues, cells, plasma/serum) with preservation of species integrity
- Strategies for preparation and characterisation of calibrants and labelled materials
- SI traceable methods for key biomarkers of MMD in biological samples (e.g. CuCER in plasma/serum; ferritin light chain in serum). Reference test material production
- Quantitative strategies for elemental spatial distribution in tissues and cells (drug penetration, effect, bio-distribution). Link to histopathology
- Feasibility evaluation of novel biomarkers of MMD (e.g. compound specific IR)
- Engagement with stakeholders (clinical research, hospitals, pharma, PT providers) to support QA schemes, disease diagnosis and the development of improved therapies



## Working closely with:

